iRhythm announced that the results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events study have been published in the American Heart Journal (AHJ). The peer-reviewed manuscript, titled "Comparative Effectiveness and Healthcare Utilization for Ambulatory Cardiac Monitoring (ACM) Strategies in Medicare Beneficiaries," reveals that the Zio long-term continuous monitoring service (LTCM), which features up to 14 continuous days of monitoring, was independently associated with the highest yield of clinical arrhythmia encounter diagnosis and lowest likelihood of retest. The prospective study of almost 300,000 patients makes CAMELOT the largest published real-world comparative effectiveness analysis of ambulatory cardiac monitoring.

AEM and MCT monitoring services were associated with statistically significantly higher costs of $1,317 and $2,372 more per patient, respectively. AEM and MCT Monitoring services were associated with statistically significantly high costs of $1,317,317 and $2,371 more per patient, respectively. The research reinforces the findings of the National Association of Managed Care Physicians, which, in an independent third-party review, found that Zio LTCM service value proposition claims are credible and objective and demonstrate high value around clinical utility and payer economics, noting that iRhythm is the first manufacturer of cardiac monitors that have conducted and published real-world comparative economic and outcome data.

Since the CAMELOT study presentation at the American College of Cardiology's 2023 Annual Scientific Sessions, these data have resulted in several health insurers updating their respective policies, ultimately removing access barriers for patients and prescribers -- updates that could positively impact nearly 17 million covered lives in the US.